

Supplementary 1. COX regression hazards ratio in univariate and multivariate analysis for PFS

	Univariate			Multivariate		
	HR	95% CI	P value	HR	95% CI	P value
Age	1.01	0.98 - 1.04	0.614			
Sex	0.96	0.41 - 2.34	0.980			
Body mass index (kg/m ²)	0.96	0.40 - 2.32	0.924			
Psoas muscle area (cm ²)	0.99	0.85 - 1.15	0.905			
Number of metastasis \geq 2	0.86	0.49 - 1.51	0.599			
Liver meta	1.22	0.62 - 2.42	0.570			
Carcinomatosis Peritonei	1.35	0.68 - 2.67	0.389			
Lung meta	1.68	0.79 - 3.57	0.180			
ECOG status 0 Vs 1/2	2.46	1.61 - 3.75	0.000*	2.46	1.61 - 3.75	0.000*
Diabetes	0.80	0.47 - 1.35	0.404			
Hypertension	2.24	1.23 - 4.10	0.009*	1.58	0.99 - 2.52	0.053
Laboratory findings						
White blood cell (/uL)	1.00	1.00 - 1.00	0.938			
Platelet (10 ³ /uL)	0.99	0.99 - 1.00	0.136			
N/L ratio	1.21	1.07 - 1.37	0.003*	1.22	1.12 - 1.33	0.000*
Platelet/Lymphocyte ratio	1.00	0.99 - 1.01	0.136			
C-reacted protein (mg/dL)	1.18	1.04 - 1.34	0.009*	1.10	0.99 - 1.23	0.077
Albumin (g/dL)	1.39	0.73 - 2.62	0.315			
Total bilirubin (mg/dL)	1.10	1.02 - 1.27	0.026*	1.08	0.99 - 1.18	0.051
CA 19-9 (U/mL)	1.00	1.00 - 1.00	0.204			

Supplementary 2. COX regression hazards ratio in univariate and multivariate analysis for OS

	Univariate			Multivariate		
	HR	95% CI	P value	HR	95% CI	P value
Age	1.03	0.99 - 1.06	0.158			
Sex	0.69	0.32 - 1.50	0.349			
Body mass index (kg/m ²)	1.01	0.91 - 1.12	0.923			
Psoas muscle area (cm ²)	0.95	0.81 - 1.10	0.477			
Number of metastasis \geq 2	0.80	0.46 - 1.41	0.444			
Liver meta	1.00	0.51 - 1.98	0.999			
Carcinomatosis Peritonei	0.72	0.38 - 1.37	0.315			
Lung meta	0.72	0.33 - 1.54	0.391			
ECOG status 0 Vs 1/2	3.50	2.08 - 5.89	0.000*	2.51	1.56 - 3.66	0.000*
Diabetes	0.92	0.54 - 1.55	0.739			
Hypertension	1.69	0.95 - 3.01	0.074			
Laboratory findings						
White blood cell (/uL)	1.00	1.00 - 1.00	0.153			
Platelet (10 ³ /uL)	1.00	0.99 - 1.00	0.747			
N/L ratio	1.35	1.17 - 1.51	0.000*	1.25	1.14 - 1.39	0.000*
Platelet/Lymphocyte ratio	0.99	0.99 - 1.00	0.062			
C-reacted protein (mg/dL)	1.18	1.02 - 1.35	0.022*	1.09	0.98 - 1.21	0.125
Albumin (g/dL)	1.07	0.59 - 1.94	0.817			
Total bilirubin (mg/dL)	1.18	1.05 - 1.32	0.004*	1.08	1.03 - 1.19	0.011*
CA 19-9 (U/mL)	1.00	1.00 - 1.00	0.637			

Supplementary 3. Prognosis according to response of CA19-9 ratio

Before chemotherapy -> post chemotherapy	Post chemotherapy CA19-9 < 300 U/mL N=63		Post chemotherapy CA19-9 ≥300 U/mL N=38		P value
	Low -> Low	High -> Low	Low -> High	High -> High	
	N=55	N=8	N=1	N=37	
PFS, median months	7.03 (5.64-8.42)		5.43 (1.84-9.02)		0.046*
(95%CI)	5.63 (3.59-7.68)	6.27 (5.12-7.42)	15.73 (N/A)	4.40 (3.11-5.69)	0.043*
OS, median months	10.17 (9.20-11.14)		9.93 (3.32-16.54)		0.053
(95%CI)	7.63 (4.18-11.08)	13.27 (6.67-19.87)	22.93 (N/A)	6.37 (5.09-7.65)	0.020*
GA Regimen	28 (50.9)	7 (87.5)	1 (100)	18 (48.6)	0.938

Low, CA19-9 < 300; high, CA19-9 ≥300; GA, Gemcitabine plus nab-paclitaxel; Post chemotherapy, evaluation at 1st tumor response of chemotherapy; N/A, not-available

Supplementary 4. Prognosis according to chemotherapy response of PLR

Before chemotherapy -> post chemotherapy	Post chemotherapy PLR < 160 N=48		Post chemotherapy PLR ≥ 160 N=53		P value
	Low -> Low	High -> Low	Low -> High	High -> High	
	N=32	N=16	N=21	N=32	
PFS, median months	5.90 (4.01-7.79)		4.90 (3.99-5.81)		0.620
(95%CI)	6.80 (5.37-8.23)	2.73 (1.44-4.02)	6.27 (3.14-9.40)	3.87 (3.68-4.06)	0.068
OS, median months	9.70 (5.40-14.0)		6.93 (5.40-8.46)		0.832
(95%CI)	10.73 (8.87-12.59)	4.40 (2.24-6.56)	8.10 (4.39-11.81)	5.33 (3.43-7.23)	0.240
GA Regimen	10 (31.3)	6 (37.5)	18 (85.7)	20 (62.5)	0.001*

Low, platelet/lymphocyte ratio < 160; high, platelet/lymphocyte ratio ≥160; GA, Gemcitabine plus nab-paclitaxel; Post chemotherapy, evaluation at 1st tumor response of chemotherapy